These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 29133712)
1. Meningiomas: Objective assessment of proliferative indices by immunohistochemistry and automated counting method. Chavali P; Uppin MS; Uppin SG; Challa S Neurol India; 2017; 65(6):1345-1349. PubMed ID: 29133712 [TBL] [Abstract][Full Text] [Related]
2. Sensitivity and usefulness of anti-phosphohistone-H3 antibody immunostaining for counting mitotic figures in meningioma cases. Fukushima S; Terasaki M; Sakata K; Miyagi N; Kato S; Sugita Y; Shigemori M Brain Tumor Pathol; 2009; 26(2):51-7. PubMed ID: 19856215 [TBL] [Abstract][Full Text] [Related]
3. Phosphohistone H3 (PHH3) as a surrogate of mitotic figure count for grading in meningiomas: a comparison of PHH3 (S10) versus PHH3 (S28) antibodies. Puripat N; Loharamtaweethong K Virchows Arch; 2019 Jan; 474(1):87-96. PubMed ID: 30267302 [TBL] [Abstract][Full Text] [Related]
4. The mitosis-specific antibody anti-phosphohistone-H3 (PHH3) facilitates rapid reliable grading of meningiomas according to WHO 2000 criteria. Ribalta T; McCutcheon IE; Aldape KD; Bruner JM; Fuller GN Am J Surg Pathol; 2004 Nov; 28(11):1532-6. PubMed ID: 15489659 [TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of the mitotic index using the mitosis marker anti-phosphohistone H3 in meningiomas. Kim YJ; Ketter R; Steudel WI; Feiden W Am J Clin Pathol; 2007 Jul; 128(1):118-25. PubMed ID: 17580279 [TBL] [Abstract][Full Text] [Related]
6. Phosphohistone-H3 Proliferation Index Is Superior to Mitotic Index and MIB-1 Expression as a Predictor of Recurrence in Human Meningiomas. Winther TL; Arnli MB; Salvesen Ø; Torp SH Am J Clin Pathol; 2016 Oct; 146(4):510-20. PubMed ID: 27686177 [TBL] [Abstract][Full Text] [Related]
7. Better see to better agree: phosphohistone H3 increases interobserver agreement in mitotic count for meningioma grading and imposes new specific thresholds. Duregon E; Cassenti A; Pittaro A; Ventura L; Senetta R; Rudà R; Cassoni P Neuro Oncol; 2015 May; 17(5):663-9. PubMed ID: 25646026 [TBL] [Abstract][Full Text] [Related]
8. Automated nuclear segmentation in the determination of the Ki-67 labeling index in meningiomas. Kim YJ; Romeike BF; Uszkoreit J; Feiden W Clin Neuropathol; 2006; 25(2):67-73. PubMed ID: 16550739 [TBL] [Abstract][Full Text] [Related]
9. Significance of Staining Intensity in Ki-67 Proliferation Index in Meningiomas, and a Critical Review of the Literature on Proliferation Index Assessment. Brasher OC; Nix JS; Gokden M Ann Clin Lab Sci; 2024 Mar; 54(2):170-178. PubMed ID: 38802155 [TBL] [Abstract][Full Text] [Related]
10. Detection of progesterone receptor and the correlation with Ki-67 labeling index in meningiomas. Mukherjee S; Ghosh SN; Chatterjee U; Chatterjee S Neurol India; 2011; 59(6):817-22. PubMed ID: 22234191 [TBL] [Abstract][Full Text] [Related]
11. Proliferative potential of recurrent intracranial meningiomas as evaluated by labelling indices of BUdR and Ki-67, and tumour doubling time. Kakinuma K; Tanaka R; Onda K; Takahashi H Acta Neurochir (Wien); 1998; 140(1):26-31; discussion 31-2. PubMed ID: 9522904 [TBL] [Abstract][Full Text] [Related]
12. The Utility of Phosphohistone H3 in Inter-Observer Variability of Mitotic Count in Meningioma, is There Any Benefit? Saffar H; Okhovat H; Arbabsoleymani S; Tavangar SM; Khoshnevisan A; Hajinasrollah G; Hamidi Afra Z; Saffar H Asian Pac J Cancer Prev; 2021 Jul; 22(7):2049-2052. PubMed ID: 34319026 [TBL] [Abstract][Full Text] [Related]
13. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases. Roser F; Samii M; Ostertag H; Bellinzona M Acta Neurochir (Wien); 2004 Jan; 146(1):37-44; discussion 44. PubMed ID: 14740263 [TBL] [Abstract][Full Text] [Related]
14. The correlation between phosphorylated Histone H3 (PHH3) and p-STAT3 in Meningiomas. Ozek E; Akdag H; Tosuner Z; Abdallah A; Hatiboglu MA Clin Neurol Neurosurg; 2019 Mar; 178():46-50. PubMed ID: 30710729 [TBL] [Abstract][Full Text] [Related]
15. PCNA, Ki-67 and hTERT in residual benign meningiomas. Maes L; Kalala JP; Cornelissen M; De Ridder L In Vivo; 2006; 20(2):271-5. PubMed ID: 16634530 [TBL] [Abstract][Full Text] [Related]
16. Mitotic Index is an Independent Predictor of Recurrence-Free Survival in Meningioma. Olar A; Wani KM; Sulman EP; Mansouri A; Zadeh G; Wilson CD; DeMonte F; Fuller GN; Aldape KD Brain Pathol; 2015 May; 25(3):266-75. PubMed ID: 25040885 [TBL] [Abstract][Full Text] [Related]
18. DNA topoisomerase II-alpha and cyclin A immunoexpression in meningiomas and its prognostic significance: an analysis of 263 cases. Korshunov A; Shishkina L; Golanov A Arch Pathol Lab Med; 2002 Sep; 126(9):1079-86. PubMed ID: 12204057 [TBL] [Abstract][Full Text] [Related]
19. Correlation of apparent diffusion coefficient with Ki-67 proliferation index in grading meningioma. Tang Y; Dundamadappa SK; Thangasamy S; Flood T; Moser R; Smith T; Cauley K; Takhtani D AJR Am J Roentgenol; 2014 Jun; 202(6):1303-8. PubMed ID: 24848829 [TBL] [Abstract][Full Text] [Related]
20. Improving precise counting of mitotic cells in mantle cell lymphoma using phosphohistone H3 (PHH3) antibody. Medani H; Elshiekh M; Naresh KN J Clin Pathol; 2021 Oct; 74(10):646-649. PubMed ID: 32873701 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]